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ReviewCancer as a Complex Genetic Trait:
Tumor Susceptibility in Humans
and Mouse Models
finding such genes is less than the cost of looking for
them. This remains to be determined, but there are rea-
sons for looking that are not simply related to potential
early stage commercial or therapeutic benefits. An un-
derstanding of the basic biological mechanisms of dis-
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San Francisco, California 94143 ease initiation and progression will only come from a
complete appreciation of the genes that influence these
steps. Identification of the variants not only provides
that information, but the exact nature of the sequenceCancer directly affects at least one-third of the human
population, but the inherited genetic determinants of changes responsible for the difference in trait may help
to pinpoint the functional domains of the protein thatcancer risk remain largely unknown. Mouse models
of human cancer are helping us to understand this impact the disease pathway. More important, however,
may be the knowledge of genetic interactions thatdisease as a complex genetic trait and thus to identify
the multiple genetic variant alleles involved in path- should emerge from these studies, since this will enable
us to build a comprehensive picture of the rate-deter-ways that affect individual cancer susceptibility.
mining pathways, rather than simply the single compo-
nents.Introduction
The human genome project has opened a Pandora’s
box of tools that have been hailed as the answer to most The Importance of Weakness
of the health problems that afflict the human population. There is substantial evidence from large scale epidemio-
We now have access not only to the DNA sequence logical studies involving monozygotic and dizygotic
itself, but to the many naturally occurring polymorphic twins that the risk of developing multiple cancer types
genetic variants that determine our individual suscepti- has a strong genetic component (Lichtenstein et al.,
bility to a host of common diseases, including cancer, 2000). Moreover, it has been shown that in families car-
cardiovascular disorders, and diabetes. The holy grail rying particular mutant alleles of “high penetrance” sus-
of postgenome drug discovery is the identification of ceptibility genes with strong effects such as the
the multiple genes that control germline predisposition neurofibromatosis type 1 (NF1) gene or breast cancer
to these complex diseases, as well as individual varia- susceptibility genes BRCA1 and 2, phenotypes are de-
tion in responses to the drugs that are used in therapy. pendent upon genetic background, being most similar
The promise of new diagnostic tools, preventive agents, between monozygotic twins, but differing between dis-
and targets for drug development has attracted much tant relatives with the same mutation (Fodor et al., 1998;
attention as well as many millions of private and public Nathanson et al., 2001). Genetic background in human
funding dollars into the hunt for the elusive genetic cul- patients is therefore able to control disease progression,
prits. Is this optimism justified, or simply an overenthusi- as has been clearly shown in animal models (Balmain
astic response to the completion of the human genome and Nagase, 1998; Nadeau, 2001), but few of these
project? This review will consider the progress and pit- “weak” human susceptibility genes have been convinc-
falls in the search for multiple genetic variants (alleles) ingly identified. Clearly, the standard gene-hunting
that influence individual susceptibility to the ravages methods that have proved so successful in the past
of cancer. The parallels, both biological and genetic, to find the single genes responsible for strong familial
between the processes of cancer development in hu- phenotypes are not readily applicable to complex dis-
mans and mice are particularly striking, leading many eases (Risch and Merikangas, 1996). Although the ge-
laboratories to exploit the mouse as a model organism netic component of risk of developing prostate cancer
for the study of this complex disease. Cancer risk in has been estimated to be over 40% (Lichtenstein et al.,
both organisms is affected by the environment and by 2000), studies involving fairly large high risk families that
genetic background, and while the major questions ulti- gave some initial cause for optimism have suffered from
mately have to be answered in humans, the mouse offers lack of confirmation in equally large studies of other
unique experimental and statistical power that can help populations (Ostrander and Stanford, 2000). This may
to unravel the complex influences of genetic back- be due to genetic heterogeneity; i.e., the causal poly-
ground on tumor susceptibility. morphisms that are responsible for the phenotype differ
There is intense debate about the ultimate value of between families. Alternatively, it may be that everyone
identifying the numerous tumor susceptibility alleles that is correct, and that there are multiple weak interacting
probably exist (variously described as tumor modifiers, loci that only reach acceptable levels of significance in
low penetrance susceptibility genes, or quantitative trait specific collections of patient samples, dependent on
loci [QTL]—see Endnote). There may be dozens or even genetic background or environmental factors. Genome-
hundreds of these alleles (Ponder, 2001), each contribut- wide searches in mouse models of cancer have revealed
ing only a small proportion of the total genetic compo- loci by virtue of genetic interactions that are not seen
nent of risk, and it has been argued that the value of as single QTLs with major effects using standard meth-
ods of analysis (van Wezel et al., 1996, Fijneman et al.,
1996, Nagase et al., 2001). More sophisticated statistical1 Correspondence: abalmain@cc.ucsf.edu
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approaches designed to detect interactions between Florentz and Sissler, 2001). Even using these ap-
proaches to reduce the total number of assays, we areloci in human familial linkage analyses may be necessary
to uncover the locations of multiple weak susceptibility unlikely to be able to carry out a respectable whole
genome scan using less than about 50,000–100,000alleles.
SNPs, and are still faced with costs of tens to hundreds
of millions of dollars for even a single comprehensiveCandidate Genes and Association Analysis
study. Although haplotyping, which exploits the frequentCandidate gene studies have led to some successes in
coinheritance of certain combinations of SNPs, may inidentifying genetic variants that modify cancer suscepti-
principle help to reduce the total number of assays, thisbility, including rare H-RAS alleles that confer increased
remains to be proven in large scale studies.risk of cancers of the breast, colorectum, and urinary
Superimposed on this already complex scenario isbladder (Krontiris et al., 1993). Risk of ovarian cancer is
the spectre of genetic interactions, which are heavilyalso increased by these rare alleles, particularly in con-
dependent on genetic background, at least in the mousecert with mutations in high penetrance mutant alleles of
and in Drosophila (van Wezel et al., 1996, Fijneman etBRCA1 (Phelan et al., 1996). Good guesswork has also
al., 1996; Mackay, 2001). Extrapolation to humans raisesunearthed variants in other candidates with obvious
the unpleasant prospect that a particular SNP may beinvolvement in cancer, such as cyclin D1 (Kong et al.,
detected as a tumor modifier in one ethnic background,2000; Bala and Peltomaki, 2001), but the vast majority
but act in the opposite direction in another population,languish unidentified in the proliferating databases of
or possibly even in different individuals within the samegenetic information now available. The candidate gene
population. While whole genome scanning is a laudableapproach is a difficult and expensive route to the identifi-
goal, clearly both financial and technological restrictionscation of susceptibility genes, as shown by a recent
apply that will prevent this kind of comprehensive analy-analysis (Dunning et al., 1999) of multiple polymor-
sis in the near future.phisms in 18 candidate genes that were reported in
small studies to show an association with breast cancer
risk. The conclusion from this study was that much larger Mouse Models of Human Cancer
In view of the problems that confound searches for hu-numbers of patients and controls are necessary to pro-
vide sufficient power to detect the levels of increased man tumor susceptibility alleles, many laboratories have
turned to the mouse as a model system that has multiplerisk conferred by most of these putative modifier genes.
advantages. The ability to control environmental expo-
sure that leads to tumorigenesis allows a focus on ge-Whole Genome Scanning
netic components of disease that is not possible withAn alternative to dependence on good guesswork would
human populations. The availability of dozens of inbredbe an unbiased method for scanning the complete ge-
strains, outbred mice of different species that have dis-nome for polymorphisms that confer increased risk. The
tinct evolutionary histories, recombinant inbreds, re-extent of linkage disequilibrium in the human genome
combinant congenics (van Wezel et al., 1996), con-is a critical determinant of the probability of success for
somics (Matin et al., 1999), Genome-Tagged Micethis approach, and current estimates range from around
(Iakoubova et al., 2001), transgenics, knockouts, knock-5–10 Kb (Kruglyak, 1999) to about 60 Kb (Reich et al.,
ins (Hasty et al., 1991), and even clones (Rideout et al.,2001). The number of single nucleotide polymorphisms
2000), provides a genetic resource that is unparalleled(SNPs) required for whole genome scans is unclear, and
among animal model systems. Mice develop cancersthe estimates range downward from an upper limit of
that look remarkably similar, in many instances, to hu-around 500,000 (Kruglyak, 1999). For genetic variants
man tumors, and in so doing, they acquire mutations inthat confer low relative risk (e.g., 1.5) and are of low to
a similar spectrum of protooncogenes and tumor sup-intermediate allele frequency (0.1–0.3) in the population,
pressor genes (Balmain and Harris, 2000). It thereforevery large numbers of patients and controls (of the order
seems likely that at least some of the large number ofof thousands rather than hundreds) would be necessary
QTLs containing tumor susceptibility/resistance genesto have a good chance of detecting an effect (Ponder,
that have been mapped using many different mouse2001). It is evident that genotyping of this magnitude
models of cancer will prove to be relevant to the human(2  10e9 genotypes for 2000 patients and matched
situation, although this remains to be firmly established.controls at 500,000 SNPs), at present day costs, is tech-
nically and financially challenging. Selection of appro-
priate candidate SNPs would reduce this number sub- The Search for Genetic Modifiers: ENU
Mutagenesis versus QTL Hunting?stantially, but the basis for choosing the candidates is
unclear. Non-sense mutations of the kind seen within These natural genetic variants should be distinguished
from mutants that are induced in the germline by treat-the Mom-1 gene (Pla2g2a) (MacPhee et al., 1995) are
unlikely to be a common occurrence in humans, and by ment with a potent mutagen such as ethyl-nitrosourea
(ENU) and that may also be capable of modifying tumoranalogy with some studies in Drosophila, many func-
tional polymorphisms may be within regulatory regions phenotypes. Various arguments have been advanced
as to the relative merits of both approaches to the detec-of genes (Mackay, 2001). Even the humble “silent” third
base mutation, often discounted as insignificant, may tion of genes that modify cancer risk in mice. Nadeau
and Frankel (2000) recently described natural QTLs ashave some functional significance since silent mutations
in yeast have been shown to be subject to selection, “accidents of history” and stated that “knowledge
gained from chemically-induced mutants will probablypossibly in conjunction with changes in sequence or
copy number of specific tRNA genes (Sharp et al., 1995; have a more immediate and profound impact on human
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health.” Their arguments seem, to say the least, prema- estingly, this number corresponds to one scenario dis-
cussed by Ponder (2001) by which between 13 and 40ture. About one hundred “natural” modifiers have been
susceptibility alleles could account for all of the ob-mapped from different model systems (Balmain and Na-
served excess familial risk of breast cancer that is notgase, 1998; Cormier et al., 2000; Talbot et al., 1999),
explained by BRCA1 and 2. It seems likely that theseand for some of these, convincing evidence has been
genetic variants may also influence the probability ofprovided for the identity of some of the critical genes
developing sporadic cancers, but this can best be ad-and polymorphisms (MacPhee et al., 1995; Cormier et
dressed when the candidate genes are identified.al., 1997; Zhang et al., 2001). In contrast, none of the
It has been argued that many of the loci detected asENU-induced tumor susceptibility/resistance alleles has
QTLs are in fact multiplets containing several individualbeen mapped or identified. While it is undoubtedly an
genes, each of which has a small effect on susceptibility.elegant idea to induce single point mutations into modi-
Direct evidence in favor of this idea has been providedfier genes that may stimulate or inhibit their activities,
by the detection of at least two genes within the Mom-1while simultaneously introducing a “tag” that can subse-
locus (Cormier et al., 2000), and similar results havequently be exploited for definitive gene identification,
been obtained from studies of QTLs associated withthe fact remains that the location of the mutant gene
susceptibility to other diseases, such as systemic lupushas to be found by genetic mapping, involving crosses
erythematosus (Morel et al., 2001). This has been pro-to other mouse genetic backgrounds. The location of
posed to be one of the major problems that confoundthe mutant allele may therefore be masked by the pres-
the identification of modifier genes, and the explanationence of natural modifiers of the phenotype that are pres-
of the “disappearance” of modifier effects during theent in the strains used for mapping. The confounding
generation of congenic mice (Legare et al., 2000). Thiseffects of the strong natural modifiers are a serious im-
interpretation has disturbing implications for estimatespediment to the use of ENU for finding the multiple
of the total number of tumor susceptibility genes. Forvariant genes that confer relatively low risk and are the
several genes to be detected as a QTL, they would havesubject of such interest in human populations. There is
to operate in the same direction (conferring resistance orno doubt that ENU mutagenesis is an extremely powerful
susceptibility), since otherwise the effects of the allelestool for the identification of critical genes that lie on
would cancel each other and the locus would be invisi-particular pathways, such as the Apc (Min) mutation
ble. In principle, there should be many loci where thisitself (Su et al., 1992). Studies with ENU mutagenised
is actually not the case; i.e., the genome should haveanimals are more likely to reveal this kind of strong
many clusters of alleles that do not operate in unison andmutation, partly because the postdoctoral fellow work-
are therefore not detected by QTL analysis. Moreover,ing on the project wants to investigate a strong effect
since there is no reason a priori for clusters of modifiersrather than a modest phenotypic change that may disap-
to exist in the first place, there should be many single-pear during the mapping process. Clearly, ENU muta-
tons that also remain below the radar screen, immunegenesis has a very important place in the armory of tools
from detection by presently available methods. We areavailable to the mouse geneticist, but it is an approach
faced with the frightening conclusion that there maythat may more usefully be applied to the detection of
be many hundreds of tumor susceptibility/resistancemutants that can be easily mapped, for example by
genes, presenting us with an almost impossibly complexexploiting regions of haploid deletions within the mouse
problem to resolve. Fortunately, however, several argu-genome (Ramirez-Solis et al., 1995). At the very least,
ments suggest that this doomsday scenario may not beuse of this approach for finding tumor susceptibility
correct. Many QTLs engage in genetic interactions thatmodifier genes could be preceded by a careful study of
greatly increase their combined effects on phenotypethe numbers and locations of natural modifiers in the
(van Wezel et al., 1996; Fijneman et al., 1996; Nagasestrains used for mutagenesis and mapping. In this way,
et al., 2001). To explain these strong interactions, we
a perturbation of the profile of modifier locations or
would have to postulate either that all of the genes within
strengths may help to localize the position of the newly
one QTL interact with all of the genes in the other, or
induced mutation. that there is only a single interacting gene at each locus
(or some combination of these two possibilities). At first
How Many Tumor Susceptibility Genes Are There? glance, the first alternative seems unlikely, but we now
At a conservative estimate, at least 100 QTLs have been know that some groups of functionally related genes
mapped as tumor susceptibility loci in various models arose by gene duplication to create tandem clusters of
of cancer. For example, skin cancer is controlled by related sequences. It is therefore possible that a func-
alleles in at least 13 loci that are detected using interspe- tional “cluster” may represent a QTL that has arisen and
cific (Mus spretus  Mus musculus) backcross mice been subject to selection because two or more of the
(Nagase et al., 1999). At least as many have been re- component genes, or different polymorphisms within
ported for lung cancer (Fijneman et al., 1998), and in- the same gene, act additively or synergistically in the
creasing numbers are being uncovered for colon, liver, same direction within a biochemical or biological path-
and other malignancies (van Wezel et al., 1999). Since way. Such an arrangement would ensure that this intra-
the total number of variant alleles that may act as genetic QTL interacting system has a high likelihood of being
modifiers will depend on the number of strains surveyed conserved within the population, since recombination
(if two strains each have the same susceptibility QTL, over short distances that would disrupt the interaction
it will not be detected in crosses between these strains), is less likely to occur (Figure 1). An example of how such
it seems likely that this number will increase, and may an intra-QTL interaction might operate was found for
the Drosophila Adh gene (Stam and Laurie, 1996) (for anultimately be at least 20–30 for each tumor system. Inter-
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identification of pairs of interacting genes (or clusters)
detected by QTL analyses.
Genetic Interactions—Lessons
from Evolutionary Genetics
The importance of genetic interactions was first empha-
sized in evolutionary terms by Sewell Wright. In a series
of papers in the early part of the last century, summa-
rized in 1980 (Wright, 1980), he presented his “shifting
balance” theory to explain evolutionary selection as a
counterpoint to the selection of single mutations ac-
cording to classical Darwinian theory. By this interpreta-
tion, a selective advantage is attained when a particular
combination of alleles is created by population admix-
ture, rather than by single point mutations. This was
originally founded on experimentation rather than theo-
retical considerations. Observations of domestic live-
stock suggested that overall improvement takes place
not from within a particular herd, but when interbreeding
takes place between herds, thus generating novel com-
binations of alleles. An obvious problem with this theory
is that if sets of alleles are required for a novel pheno-
type, these sets would be disrupted by further recombi-
Figure 1. Origins of QTLs nations leading to separation of the individual compo-
(1) QTLs could arise if a new mutation occurs that alters the pheno- nents. Thus, the phenotype would rapidly be lost unless
type (e.g., a change to a C in gene A). This change could have an
the population remains small. The possibility that en-effect on its own, or may be silent unless it shows a strong interaction
hanced functional gene clusters are generated by “intra-(bracket) with another gene B.
QTL” recombinations during crossbreeding helps to re-(2) A QTL may arise as a result of recombination between two alleles
of the same gene (A and A), generating a combination of polymor- solve this problem, since the newly generated allele
phisms that specify an enhanced phenotype. These polymorphisms combinations are more likely to be passed on intact to
may act synergistically within gene A (see Mackay, 2001, for discus- subsequent generations (Figure 1).
sion of intragenic polymorphisms in the Drosophila Adh gene), or
A striking example of the powerful effects of combina-may induce an interaction with another gene or QTL (B).
tions of alleles was observed in studies of recombinant(3) Recombination may occur by interbreeding of animals carrying
congenic strains that develop radiation-induced tumorsdifferent clusters of genes that form a functional unit. Recombination
may give rise to combinations of alleles that form an enhanced (Szymanska et al., 1999). Using a series of 20 CcS/Dem
functional cluster through “intra-QTL” interactions, or induce inter- (CcS) Recombinant Congenic Strains, each carrying a
actions with other QTLs. different random set of 12.5% of genes of the resistant
strain STS/A (STS) on the genetic background of the
susceptible strain BALB/cHeA (BALB/c), it was found
excellent discussion, see Mackay, 2001). Three separate that myelocytic tumors, which are rare or absent in the
polymorphisms within this gene accounted for the differ- parental strains, developed with high frequency in one
ence in expression between Fast and Slow acting alleles of the CcS strains. Although the same alleles are present
of the enzyme. in the parental strains, a unique set was proposed to
It would also be expected that if functional clusters be responsible for this phenotype. Although the possibil-
exist, interactions are also likely to occur between clus- ity of a new mutation has not yet been excluded, these
ters, and would be detected as interacting QTLs of the results support the concept of the importance of genetic
type found from mouse studies (Figure 1). Although clus- interactions in determining cancer phenotypes.
ters that have been characterized tend to consist of
genes that show sequence homology because of dupli- How Do We Find Weak Tumor
cation events, it may be predicted that functional clus- Susceptibility Genes?
ters are not necessarily dependent on sequence, but For human studies, the answer at present is to make a
arise because the component genes have been shuffled good guess about candidate genes. For the mouse,
into the same region, and selected because of interac- more structured approaches are available, all of them
tions within the cluster and/or between clusters. Recent with their own sets of problems and caveats. The basic
evidence from analysis of the human genome sequence steps in modifier gene identification in the mouse are:
supports the idea that functional clusters exist (Wright
et al., 2001), as has also been reported for the yeast 1. Identify a QTL by linkage analysis that reaches a
minimum level of significance according to ac-genome (Cohen et al., 2000). It therefore seems likely
that at least some of the QTL interactions that have been cepted criteria;
2. refine the region containing the QTL to an intervaldescribed represent functional interactions between
clusters of genes, although it is also possible that strong suitable for positional cloning (1–2 Mb) by deriving
congenic mice;interactions between single alleles within different QTLs
also occur. Resolution of these questions awaits the 3. identify candidate genes in the region;
Review
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4. identify functional or regulatory polymorphisms in of QTLs and haplotyping to refine the positions of the
loci—can be accomplished simultaneously using thethe critical gene;
5. prove that this is the modifier gene in vivo by trans- strategy outlined in Figure 2. Mus spretus is a species
of mouse that diverged from Mus musculus about threegenic or preferably knockin approaches.
million years ago, but retains the capacity to breed with
inbred Mus musculus, generating interspecific F1 hybridSome of the breeding strategies that have been devel-
mice. Although the male progeny of such crosses areoped to approach these goals, and their inherent difficul-
sterile, the females are fertile and can be used to pro-ties, have been discussed previously (Nadeau and Fran-
duce a backcross generation. We have previously identi-kel, 2000; Darvasi, 1998; Flint and Mott, 2001). The major
fied multiple QTLs for skin carcinogenesis using suchdifficulty associated with stages 1–2 is the refinement
crosses, since Mus spretus appear to carry multipleof the initial locus to a region of appropriate size for
resistance alleles for this and other tumor types. Sincepositional cloning or candidate screening. Traditionally,
the original Mus spretus mice were outbred, thesethis has been accomplished by generating congenic
crosses can be used for both linkage analysis and haplo-mice that carry a small fragment of the genome from
typing. The linkage analysis in the backcross providesone parental strain on the background of the other strain.
information on the locations of major QTLs, and haplo-For a disease such as cancer, the phenotyping that has
typing can then be used to refine the locations of theto be carried out at each breeding stage to verify the
QTLs to smaller intervals without the necessity for gen-continued presence of the susceptibility/resistance al-
erating congenic mice. Interestingly, a similar strategylele is substantial, and it has been observed that in many
involving crosses between outbred heterogeneouscases the effect disappears as breeding progresses,
stocks of Mus musculus with inbred Mus musculus waseither because of the presence of multiple genes within
proposed at least as a theoretical resolution to this prob-the interval that contribute to the effect and which are
lem (Mott et al., 2000). This approach may encountersuccessively lost during breeding, or because of the
difficulties when it is eventually tested, because of therequirement for interacting genes that may be present
overall similarity between the genomes of the parentalin other chromosomal regions (Legare et al., 2000). For
stocks of mice, where allele sharing is common. Inter-these reasons, other approaches that exploit as much
specific crosses involving Mus spretus do not suffergenetic information as possible in the initial screen are
from this drawback, since in general both parentalbeing developed to circumvent the requirement for gen-
spretus alleles can be easily distinguished from anyerating congenic lines. A behavioral trait QTL was
musculus allele in the backcross. Of course, even aftermapped to about a 1 cM interval using an outbred stock
localization of the QTL to a 1 cM interval, further prob-of mice that have been bred over several decades start-
lems exist in pinpointing the candidate gene within theing from eight different inbred mouse strains (Talbot et
interval and in identifying the critical polymorphism. Al-al., 1999). The high number of recombinations in these
though the availability of the complete mouse sequenceanimals provides a level of resolution for the mapping
from public and private databases enormously simplifiesof QTLs that is not attainable by normal linkage analysis.
sequence comparisons between strains and individualIt has recently been proposed that simple compari-
mice, since all candidates are accessible in silico, asons of the haplotypes of various inbred strains, first
large number of potential functional polymorphisms willemployed to identify a locus conferring resistance to
have to be screened. For this reason, it is desirable toparasite infection (Malo et al., 1994), can be used for
have several strains of mice that have functional QTLsprimary localization of QTLs without having prior knowl-
for the same phenotype that have been mapped to theedge based on mouse crosses (Manenti et al., 1999;
locus in question, since this will help to narrow downGrupe et al., 2001). In the latter study, SNP genotyping
the range of possible candidates.analysis revealed common haplotypes among several
mouse strains that shared one of ten different pheno-
typic traits. Some of the regions coincided with QTLs Somatic Alterations Involving Modifier Genes?
Researchers in the field of cancer genetics, as opposedthat had been mapped in crosses between particular
inbred strains, suggesting that the haplotyping method to those who study other complex diseases, have the
advantage that the tumors select out the genes of inter-could identify susceptibility loci. However, there are vari-
ous problems associated with these approaches. The est and frequently tag them by mutation, amplification,
or deletion. The paradigm provided by the classical tu-number of chromosomes tested was small, and the fact
that two inbred strains have a similar phenotype does mor suppressor genes such as Rb and P53 is that tumor
development in individuals carrying germline mutationsnot mean that they harbor the same set of susceptibility
alleles. Since there are many different QTLs that have is associated with loss of the wild-type functional allele
(Cavenee et al., 1983). These high penetrance mutationsbeen identified from mapping studies, animals that show
the same level of sensitivity may in fact have different provide a very strong driving force for loss of the re-
maining allele by whole chromosome nondisjunction orcombinations of resistance or susceptibility alleles that
produce the same end result. It would seem prudent, mitotic recombination, but it is unclear at present
whether the same applies to weaker susceptibility al-before embarking on cloning of a genetic modifier based
on haplotyping, to have information suggesting that the leles, which have more subtle effects on cell growth and
behavior. The situation is rendered more complex bystrains that share haplotypes also have the same com-
plement of functional QTLs. the multiplicity of alleles, and by the possible presence
of negatively and positively acting susceptibility/resis-These two major stages of QTL identification—
linkage analysis to identify the approximate locations tance alleles on the same chromosome. From mouse
Cell
150
models, the existence of somatic evidence for the pres-
ence of germline tumor modifiers is quite convincing,
since some model systems have been shown to exhibit
very high frequency loss of one parental allele in a high
proportion of tumors (Radany et al., 1997; Linardopoulos
et al., 2000). However, it has not yet been convincingly
demonstrated that a resistance or susceptibility QTL
exists at the location of the somatic genetic change in
tumors.
It seems likely that the complex genetic alterations
seen in human tumors are also driven by the genetic
constitution of the host, together with selection at the
somatic cell level. It might be expected that the resis-
tance allele would be lost or inactivated during tumori-
genesis, while the opposite would be the case for a
susceptibility allele. This would not be expected to be
the case for all genetic modifiers, but only for those
that act cell autonomously within the target tumor cells.
Genetic modifiers that act non-cell autonomously in
stromal or endothelial cells, or as components of the
immune system, would not be expected to be the target
of direct changes leading to altered function within the
tumors. One corollary of this hypothesis is that allele-
specific somatic changes in human tumors should point
us toward the locations of a subset of germline suscepti-
bility alleles. Again, the mouse offers some distinct ad-
vantages for studies of this kind, since we know in ad-
vance the provenance of the susceptibility or resistance
alleles involved.
One implication of the discussion above on clusters
of functionally related genes within QTLs is that there
may be no single genetic culprit within regions that show
frequent deletions or loss of heterozygosity (LOH) in
human tumors. Haploinsufficiency at tumor suppressor
gene loci can make a powerful contribution to suscepti-
bility to neoplasia (Tang et al., 1998; Fero et al., 1998;
Inoue et al., 2001), and this effect may be particularly
strong if alleles of several functionally related (possibly
interacting) genes within the same locus are simultane-
ously deleted. The gold standard for identification of
a tumor suppressor gene has been the detection of
inactivating point mutations in the single allele remaining
after an LOH event. These signature mutations may be
rare or absent in situations where the whole QTL com-
prising several alleles is hemizygous. Mouse models
again offer the prospect of testing these possibilities
through the generation of nested sets of deletions at
QTL loci (Ramirez-Solis et al., 1995) to assess the effectsFigure 2. Standard Linkage Analysis Is Normally Carried out by Ge-
of hemizygous loss on tumor susceptibility.notyping Backcross (a) or Intercross (not shown) Progeny from Two
Inbred Strains (A and B) of Mus musculus
Microsatellite or SNP markers can be used to distinguish the alleles How Can We Make Humans More Like Mice?
from the two parental strains. This strategy usually identifies loci The power of mouse genetics lies in the ability to gener-
within regions of about 10–30 cM. (b). Using outbred mice from a ate crosses between families of mice that are genetically
different species (Mus spretus), the same backcross strategy can
highly susceptible or highly resistant to cancer, andbe used as in (a) to provide similar linkage data. In addition, the
trace the genes that affect these phenotypes. This is ofoutbred nature of the parental spretus mice can be exploited to
course not possible in humans, and the closest we canidentify specific smaller regions of the genome that are shared by
backcross progeny that have the same phenotype. The spretus mice get may be to search among the progeny of individuals
are heterozygous at many markers, and frequently both alleles differ carrying high penetrance mutations for variations in phe-
from those present in the inbred Mus musculus strain used in the notypes that could be explained by genetic modifiers.
backcross. An allele conferring resistance to tumor development
Examples exist of family pedigrees with BRCA1 or 2(red box denoted by the arrowhead) can be localized with higher
mutations that have either early or late onset of tumorresolution by comparing haplotypes among the phenotyped
development, and studies are in progress to try to findprogeny.
these genes by linkage analysis (Nathanson et al., 2001).
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phospholipase Pla2g2a confers resistance to intestinal tumorigene-Collections of non-BRCA1/2 families have been made
sis. Nat. Genet. 17, 88–91.in an attempt to find BRCA3, and we await the results
Darvasi, A. (1998). Experimental strategies for the genetic dissectionof such analyses with interest. Most analyses of human
of complex traits in animal models. Nat. Genet. 18, 19–24.pedigrees are still focused on the possibility that one
Dietrich, W.F., Lander, E.S., Smith, J.S., Moser, A.R., Gould, K.A.,or very few strong genes may account for the “lost”
Luongo, C., Borenstein, N., and Dove, W. (1993). Genetic identifica-genetic component of susceptibility. While there may
tion of Mom-1, a major modifier locus affecting Min-induced intesti-
still be some (almost) high penetrance genes to be nal neoplasia in the mouse. Cell 75, 631–639.
found, the likelihood is that we will be faced with the
Dunning, A.M., Healey, C.S., Pharoah, P.D., Teare, M.D., Ponder,
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